Cargando…

Four-factor prothrombin complex concentrate (Beriplex® P/N) mediated reversal of apixaban-induced bleeding in a rabbit model

Detalles Bibliográficos
Autores principales:	Herzog, E, Kaspereit, F, Krege, W, Mueller-Cohrs, J, Doerr, B, Niebl, P, Dickneite, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471498/ http://dx.doi.org/10.1186/cc14428

Ejemplares similares

Four‐factor prothrombin complex concentrate reverses apixaban‐associated bleeding in a rabbit model of acute hemorrhage
por: Herzog, E., et al.
Publicado: (2015)

Reversal of edoxaban-induced anticoagulation by the four-factor prothrombin complex concentrate Beriplex(® )in a rabbit model
por: Herzog, E, et al.
Publicado: (2014)

Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
por: Herzog, E, et al.
Publicado: (2015)

Acquired bleeding model induced by dilutional coagulopathy in the rabbit
por: Pragst, I, et al.
Publicado: (2009)

Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models
por: Ghosh, Subhajit, et al.
Publicado: (2021)

Prothrombin complex concentrate mitigates diffuse bleeding after cardiopulmonary bypass in a porcine model
por: Kaspereit, F., et al.
Publicado: (2010)

Treatment of the coagulation deficit during extracorporeal circulation in a porcine model by a prothrombin complex concentrate
por: Kaspereit, F, et al.
Publicado: (2010)

Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital
por: Bruce, David, et al.
Publicado: (2008)

Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation
por: Chowdary, Pratima, et al.
Publicado: (2018)

Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy Volunteers
por: Nagalla, S, et al.
Publicado: (2016)

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Comparison of prothrombin complex concentrate and fresh frozen plasma on thrombin generation and hemorrhage in experimental dilutional coagulopathy
por: Dickneite, G, et al.
Publicado: (2008)

Feasibility and clinical effectiveness of pre-hospital prothrombin complex concentrates (Octaplex/Beriplex) in anticoagulated patients with traumatic intracranial haemorrhage
por: Brooks, Ben, et al.
Publicado: (2015)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study
por: Hanke, A. A., et al.
Publicado: (2013)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model
por: Dickneite, G., et al.
Publicado: (2009)

Reversal of oral anticoagulation with prothrombin complex concentrate (Octaplex)
por: Riess, H, et al.
Publicado: (2007)

Prothrombin complex concentrate use in surgical patients: a retrospective analysis of efficacy and safety for coumarin reversal and bleeding management
por: Schick, KS, et al.
Publicado: (2008)

Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Evaluation of fixed dose four-factor prothrombin complex concentrate for warfarin reversal at a level 1 trauma center
por: Drone, H, et al.
Publicado: (2015)

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
por: Costa, Olivia S., et al.
Publicado: (2022)

Correction to: Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro
por: Schultz, Nina H., et al.
Publicado: (2017)

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
por: Schultz, Nina Haagenrud, et al.
Publicado: (2018)

Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists
por: Rodriguez, Vilmarie, et al.
Publicado: (2022)

Efficacy and safety of activated prothrombin complex concentrate for the reversal of vitamin K antagonist major bleeding
por: Sheikh-Taha, Marwan, et al.
Publicado: (2022)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
por: Schenk, Bettina, et al.
Publicado: (2018)

Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding
por: Schick, Kerstin S, et al.
Publicado: (2009)

Using of prothrombin complex concentrate in patients with trauma-induced coagulopathy
por: Tarabrin, O, et al.
Publicado: (2015)

Use of four‐factor prothrombin complex concentrate for the mitigation of rivaroxaban‐induced bleeding in an emergent coronary artery bypass graft
por: Liu, Michael, et al.
Publicado: (2017)

Efficacy of non-specific hemostatic agents for reversal of prophylactic apixaban levels
por: Schmidt, K, et al.
Publicado: (2015)

Efficacy of idarucizumab, prothrombin complex concentrate (PCC) and activated PCC to reverse the anticoagulatory potential of dabigatran in a porcine polytrauma model
por: Honickel, M, et al.
Publicado: (2015)

The role of prothrombin complex concentrates in reversal of target specific anticoagulants
por: Babilonia, Katrina, et al.
Publicado: (2014)

Acquired deficiency of prothrombin complex coagulation factors in major bleeding is a therapeutic indication of 4‐factor prothrombin complex concentrates
por: Wiedermann, Christian J.
Publicado: (2020)

Octaplex in routine clinical use for prophylaxis and therapy of bleeding in patients with prothrombin complex factor deficiency
por: Franken, T, et al.
Publicado: (2007)

Prothrombin complex concentrate in the management of major bleeding induced by oral anticoagulant therapy
por: AlSheef, Mohammed, et al.
Publicado: (2022)

In a trauma experimental pig model prothrombin complex concentrates and a specific antidote (idarucizumab) are effective to reverse the anticoagulant effects of dabigatran
por: Grottke, O, et al.
Publicado: (2014)

Apixaban: Gastrointestinal bleeding: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gbquu0qlod14hnuttalnim6cbd